Girard Partners Ltd. Bristol Myers Squibb CO Transaction History

Girard Partners Ltd.

  • $1.06 Billion
  • Q1 2024

A detailed history of Girard Partners Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Girard Partners Ltd. holds 28,605 shares of BMY stock, worth $1.13 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
28,605
Previous 30,568 6.42%
Holding current value
$1.13 Million
Previous $1.57 Million 1.08%
% of portfolio
0.15%
Previous 0.16%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$47.98 - $54.4 $94,184 - $106,787
-1,963 Reduced 6.42%
28,605 $1.55 Million
Q4 2023

Feb 09, 2024
SELL
$48.48 - $57.85 $138,604 - $165,393
-2,859 Reduced 8.55%
30,568 $1.57 Million
Q3 2023

Nov 02, 2023
BUY
$57.89 - $64.73 $85,561 - $95,670
1,478 Added 4.63%
33,427 $1.94 Million
Q2 2023

Aug 15, 2023
BUY
$63.71 - $70.74 $207,248 - $230,117
3,253 Added 11.34%
31,949 $2.04 Million
Q1 2023

May 12, 2023
SELL
$65.71 - $74.53 $109,998 - $124,763
-1,674 Reduced 5.51%
28,696 $1.99 Million
Q4 2022

Jan 26, 2023
BUY
$68.48 - $81.09 $133,125 - $157,638
1,944 Added 6.84%
30,370 $0
Q3 2022

Oct 20, 2022
SELL
$0.13 - $76.84 $23 - $13,984
-182 Reduced 0.64%
28,426 $2.02 Million
Q2 2022

Jul 26, 2022
BUY
$72.62 - $79.98 $1.8 Million - $1.98 Million
24,760 Added 643.45%
28,608 $2.2 Million
Q1 2022

Apr 27, 2022
SELL
$61.48 - $73.72 $10,513 - $12,606
-171 Reduced 4.25%
3,848 $281,000
Q4 2021

Feb 02, 2022
SELL
$53.63 - $62.52 $9,867 - $11,503
-184 Reduced 4.38%
4,019 $250,000
Q3 2021

Nov 01, 2021
BUY
$59.17 - $69.31 $234,017 - $274,121
3,955 Added 1594.76%
4,203 $248,000
Q3 2021

Nov 01, 2021
SELL
$59.17 - $69.31 $254,194 - $297,755
-4,296 Reduced 94.54%
248 $248,000
Q2 2021

Aug 10, 2021
SELL
$61.91 - $67.42 $41,293 - $44,969
-667 Reduced 12.8%
4,544 $303,000
Q1 2021

May 06, 2021
SELL
$59.34 - $66.74 $102,124 - $114,859
-1,721 Reduced 24.83%
5,211 $329,000
Q4 2020

Feb 02, 2021
SELL
$57.74 - $65.43 $68,768 - $77,927
-1,191 Reduced 14.66%
6,932 $429,000
Q3 2020

Nov 13, 2020
SELL
$57.43 - $63.64 $157,587 - $174,628
-2,744 Reduced 25.25%
8,123 $489,000
Q2 2020

Aug 10, 2020
SELL
$54.82 - $64.09 $233,039 - $272,446
-4,251 Reduced 28.12%
10,867 $639,000
Q1 2020

May 01, 2020
SELL
$46.4 - $67.43 $322,201 - $468,233
-6,944 Reduced 31.47%
15,118 $842,000
Q4 2019

Feb 03, 2020
BUY
$49.21 - $64.19 $403,768 - $526,678
8,205 Added 59.21%
22,062 $1.42 Million
Q3 2019

Nov 01, 2019
SELL
$42.77 - $50.71 $409,822 - $485,903
-9,582 Reduced 40.88%
13,857 $702,000
Q2 2019

Aug 12, 2019
BUY
$44.62 - $49.34 $182,495 - $201,800
4,090 Added 21.14%
23,439 $1.06 Million
Q1 2019

May 08, 2019
SELL
$45.12 - $53.8 $9,339 - $11,136
-207 Reduced 1.06%
19,349 $923,000
Q4 2018

Feb 11, 2019
SELL
$48.76 - $63.23 $110,538 - $143,342
-2,267 Reduced 10.39%
19,556 $1.02 Million
Q3 2018

Nov 09, 2018
SELL
$55.19 - $62.25 $308,788 - $348,288
-5,595 Reduced 20.41%
21,823 $1.35 Million
Q2 2018

Aug 07, 2018
SELL
$50.53 - $62.98 $57,048 - $71,104
-1,129 Reduced 3.95%
27,418 $1.52 Million
Q1 2018

Apr 18, 2018
SELL
$59.92 - $68.98 $44,820 - $51,597
-748 Reduced 2.55%
28,547 $1.81 Million
Q4 2017

Feb 07, 2018
SELL
$59.94 - $65.35 $48,491 - $52,868
-809 Reduced 2.69%
29,295 $1.8 Million
Q3 2017

Nov 08, 2017
SELL
$55.23 - $63.74 $135,810 - $156,736
-2,459 Reduced 7.55%
30,104 $1.92 Million
Q2 2017

Aug 08, 2017
BUY
N/A
32,563
32,563 $1.81 Million

Others Institutions Holding BMY

# of Institutions
2,553
Shares Held
1.49B
Call Options Held
25.9M
Put Options Held
20M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $84.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Girard Partners Ltd. Portfolio

Follow Girard Partners Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Girard Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Girard Partners Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email